Literature DB >> 11123719

Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model.

S B Wharton1, U McNelis, H S Bell, I R Whittle.   

Abstract

Development of necrosis is a characteristic feature of glioblastoma but its pathogenesis remains poorly understood. The process of poly(ADP-ribosyl)ation in response to DNA damage is mediated by poly(ADP-ribose) polymerase (PARP) and results in NAD+ depletion. The consequent ATP and energy depletion may result in cell necrosis. Therefore PARP activation is a potential candidate for a regulatory role in the pathogenesis of necrosis in glioblastoma. This study investigated whether there might be a relationship between both PARP expression and poly(ADP-ribosyl)ation, and necrosis in glioblastoma. The pattern of expression of PARP and of poly(ADP-ribose) groups in an archival series of glioblastoma was examined using immunohistochemistry. These parameters were also studied in multicellular tumour spheroids, derived from human glioma cell lines in which central necrosis develops with increasing spheroid diameter. Poly(ADP-ribose) groups were expressed in peri-necrotic tumour cells in glioblastoma. In the spheroid model poly(ADP-ribosyl)ation was seen centrally in pre-necrotic and necrotic cells with increasing spheroid diameter. PARP was widely expressed in viable tumour cells in the glioblastoma sections. In the spheroids, PARP expression, which was initially diffuse, became confined to the outer proliferative zone with increasing diameter. The pattern of expression of poly(ADP-ribose) groups in the spheroids and in glioblastoma raises the possibility that poly(ADP-ribosyl)ation may play a role in the development of necrosis in glioma. The high basal PARP expression in both glioblastoma and the spheroids suggests that this enzyme may have additional roles in glioma cell biology.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11123719     DOI: 10.1046/j.0305-1846.2000.00288.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  11 in total

1.  The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.

Authors:  Xiaozhe Wang; David T Weaver
Journal:  Am J Cancer Res       Date:  2010-01-03       Impact factor: 6.166

Review 2.  Neuropathology for the neuroradiologist: palisades and pseudopalisades.

Authors:  F J Wippold; M Lämmle; F Anatelli; J Lennerz; A Perry
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

Review 3.  Trial watch - inhibiting PARP enzymes for anticancer therapy.

Authors:  Antonella Sistigu; Gwenola Manic; Florine Obrist; Ilio Vitale
Journal:  Mol Cell Oncol       Date:  2015-06-10

Review 4.  The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence.

Authors:  Brenda Auffinger; Drew Spencer; Peter Pytel; Atique U Ahmed; Maciej S Lesniak
Journal:  Expert Rev Neurother       Date:  2015-05-31       Impact factor: 4.618

5.  Pediatric high-grade glioma: identification of poly(ADP-ribose) polymerase as a potential therapeutic target.

Authors:  Stuart J Smith; Angela Long; Jennifer H Barrow; Donald C Macarthur; Beth Coyle; Richard G Grundy
Journal:  Neuro Oncol       Date:  2011-08-17       Impact factor: 12.300

6.  Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

Authors:  Ruth Plummer; Christopher Jones; Mark Middleton; Richard Wilson; Jeffrey Evans; Anna Olsen; Nicola Curtin; Alan Boddy; Peter McHugh; David Newell; Adrian Harris; Patrick Johnson; Heidi Steinfeldt; Raz Dewji; Diane Wang; Lesley Robson; Hilary Calvert
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

7.  HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration.

Authors:  Rosaria Bassi; Paola Giussani; Viviana Anelli; Thomas Colleoni; Marco Pedrazzi; Mauro Patrone; Paola Viani; Bianca Sparatore; Edon Melloni; Laura Riboni
Journal:  J Neurooncol       Date:  2007-11-02       Impact factor: 4.130

Review 8.  Pivotal role of high-mobility group box 1 (HMGB1) signaling pathways in glioma development and progression.

Authors:  Efthalia Angelopoulou; Christina Piperi; Christos Adamopoulos; Athanasios G Papavassiliou
Journal:  J Mol Med (Berl)       Date:  2016-06-04       Impact factor: 4.599

9.  Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates.

Authors:  Jodi A Muscal; Patrick A Thompson; Vincent L Giranda; Brian D Dayton; Joy Bauch; Terzah Horton; Leticia McGuffey; Jed G Nuchtern; Robert C Dauser; Brian W Gibson; Susan M Blaney; Jack M Su
Journal:  Cancer Chemother Pharmacol       Date:  2009-06-13       Impact factor: 3.333

10.  PARP-1 protein expression in glioblastoma multiforme.

Authors:  A Galia; A E Calogero; R Condorelli; F Fraggetta; A La Corte; F Ridolfo; P Bosco; R Castiglione; M Salemi
Journal:  Eur J Histochem       Date:  2012-02-27       Impact factor: 3.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.